HOME >> MEDICINE >> NEWS
Preventing toxic side effects of inflammatory disease therapy

Researchers at the University of California, San Diego (UCSD) School of Medicine have developed a mouse model that could help scientists develop better drugs to fight autoimmune and inflammatory disorders such as multiple sclerosis and rheumatoid arthritis.

Inflammation is a process by which the white blood cells and chemicals of the immune system rally to protect the body from infection and foreign substances such as bacteria and viruses. In autoimmune diseases, however, this defense system triggers an inflammatory response when there are no foreign substances to fight off, or the defense system goes into "overdrive" and forgets how to turn off. In these diseases, the body's normally protective immune system attacks and damages its own healthy tissues.

UCSD researcher Mark H. Ginsberg, M.D., professor of Medicine at the University of California, San Diego (UCSD) School of Medicine, and his colleagues have identified a mechanism to selectively disrupt signaling to recruit lymphocytes and monocytes white blood cells sent to sites of inflammation to fight infection while maintaining the body's other essential immune system functions. Their findings appear online on February 9 in advance of print publication in the March issue of the Journal of Clinical Investigation.

In the case of certain autoimmune diseases, the alpha 4 integrins cause white blood cells to accumulate at the site of the disease, resulting in inflammation. An integrin is a surface molecule found on the exterior of cells that helps cells adhere and migrate. It is also believed to be responsible for a role in cell signaling, which allows cells to communicate with the extracellular environment. One of the promising treatments for disorders such as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis the alpha 4 integrin antagonist works by blocking cell adhesion. However, this anti-inflammatory therapy could cause adverse side effects, such as impairme
'"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
8-Feb-2006


Page: 1 2 3

Related medicine news :

1. IOM Advisory: Preventing Medication Errors News Conference on July 20
2. Preventing spinal cord injury during aortic surgery
3. An ISN Bellagio Summit - Preventing vascular diseases around the world
4. Preventing another Vioxx
5. Preventing pneumonia in children helps prevent pneumonia in older adults
6. Preventing chronic diseases - need for concerted action
7. Preventing communication errors in telephone medicine
8. Draining away brains toxic protein to stop Alzheimers
9. Report calls for new directions, innovative approaches in testing chemicals for toxicity to humans
10. New system for reporting toxicity burden of cancer treatment
11. Smokeless cannabis delivery device efficient and less toxic

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... 30, 2017 , ... According to the American Society of Plastic Surgeons (ASPS), ... the top 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, ... over the next 8-10 weeks. For anyone considering a hair removal procedure, there are ...
(Date:3/30/2017)... ... March 30, 2017 , ... AudioEducator, a ... “ Preventing Hospital Readmissions Through Discharge Planning ” with noted expert Sue Dill ... This conference discusses strategies to prevent readmissions in light of the most recent ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... women’s professional squash, announced it has enlisted New York City-based sports and entertainment ... will develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which ...
(Date:3/29/2017)... Petersburg, FL (PRWEB) , ... March 30, 2017 , ... ... called the "Spice of Life" or "Wonder Spice", it has been used for thousands ... use in the East," says Heshelow, author of " Turmeric: How to Use it ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, ... Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx in ... of the study is to determine the dose level ... a planned Phase 3 cardiovascular outcome study. ... collaboration with Novartis to develop and commercialize drugs to ...
(Date:3/29/2017)... QUEBEC CITY , March 29, 2017 /PRNewswire/ ... Food and Drug Administration (FDA) 510(k) clearance for ... launch of this truly personalized orthopaedic restoration. Bodycad ... clearance for a joint reconstruction implant system. ... designed to optimize personalized restoration of the patient,s ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology:
Cached News: